Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

Creative Commons License

Yeter H. H., Derici Ü., Arinsoy T., Altok K., Erten Y., Güz G.

ROMANIAN JOURNAL OF INTERNAL MEDICINE, cilt.60, sa.1, ss.56-65, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2478/rjim-2021-0034
  • Dergi Adı: ROMANIAN JOURNAL OF INTERNAL MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.56-65
  • Anahtar Kelimeler: atypical hemolytic uremic syndrome, eculizumab, therapeutic plasma exchange, discontinuation, prognosis, MANAGEMENT, CONSENSUS, DIAGNOSIS, OUTCOMES
  • Gazi Üniversitesi Adresli: Evet

Özet

Introduction: To evaluate the effect of therapeutic plasma exchange(TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome(aHUS). Additionally, to examine the reliability of discontinuation of eculizumab treatment.